Christopher Boyer, BSc, MBA
CEO & Executive Director
Co-founder. Twenty years building biotechnology companies in Australia and the United States.
About
Proving the power of GPI-targeted SSCVs
Founded in Melbourne in 2024. Phase I clinical trials in 2027, partnering after feasibility in humans. We invite investors and commercial development partners to join our mission to defeat the world’s deadliest infectious diseases.
Christopher Boyer and Distinguished Professor Louis Schofield, BIO International Convention.
Founders
Distinguished Professor Louis Schofield
CSO & Executive Director
Co-founder and inventor. Professor Schofield devoted his life’s work to defeating malaria. He identified GPI as the principal malaria toxin, and published in Nature that immunisation with a synthetic GPI glycan protected mice against severe malarial disease. He was inaugural Director of the Australian Institute of Tropical Health and Medicine in Cairns, where he invented novel compositions and expanded methods of use for GPI-targeting SSCVs.
Advisors
Renaud Jacquemart, PhD, MBA
Advisor, pharma partnering
North America–based. CMC oversight and a global network across vaccine manufacturers.
Davi La Ferla, BSc, MBA
Advisor, corporate development
Investment strategy and commercial positioning.
Alison Cook, MSc
Advisor, CMC
GMP manufacturing, CMC strategy and CDMO oversight — including prior management of ST101 development.
Intellectual property
Composition-of-matter and method-of-use patents covering optimal molecular design, prevention and treatment across a range of diseases, and combinations that potentiate other vaccines. Proprietary manufacturing and GLP-toxicology packages are exclusively licensed from DMTC Limited, including work funded by Australian Defence. Related IP was acquired from James Cook University.
Melbourne
Saccharide Therapeutics Pty LtdLevel 17, HWT Tower
40 City Road
Southbank VIC 3006
Australia